Zhejiang Huahai Pharmaceutical (SHA:600521) obtained registration for two drugs from China's medical products administrator.
Brexpiprazole tablets are indicated for adult schizophrenia and isavuconazonium sulfate injection for invasive aspergillosis and mucormycosis, according to a weekend filing with the Shanghai bourse.
Shares of the drugmaker closed 1% higher Monday.